CELC
Celcuity Inc.
Biotechnology · Healthcare · United States
69.13
close · 2026-10-30
value
96
cheaper than peers96
quality
4
stronger fundamentals4
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 2 years ago | -1.6% | 94 |
| earnings yield, 2 years ago | -3.9% | 94 |
| cash flow yield, 3 years ago | -1.1% | 93 |
| earnings yield, 3 years ago | -3.8% | 91 |
| earnings yield, 1 year ago | -4.1% | 89 |
| cash flow yield, 1 year ago | -2.5% | 88 |
| earnings yield, latest year | -5.5% | 86 |
| cash flow yield, latest year | -4.5% | 83 |
| price to book | 83.11× | 1 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| debt to equity | 604.3% | 2 |
| return on equity | -1433.7% | 0 |
3 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | -$72.0M |
| employees | 155 |
| first trade | 2017-09-20 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-09-01 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -3.79 | -2.83 | -2.69 | -2.64 | not reported |
| free cash flow | -$153.5M | -$83.7M | -$53.9M | -$36.2M | not reported |
| net income | -$177.0M | -$111.8M | -$63.8M | -$40.4M | not reported |
| revenue | $0 | $0 | $0 | $0 | not reported |
| unusual items | not reported | not reported | not reported | $0 | -$263 |